Loading...
CGC logo

Canopy Growth CorporationNasdaqGS:CGC 株式レポート

時価総額 US$402.5m
株価
US$1.04
US$1.7
38.7% 割安 内在価値ディスカウント
1Y-43.2%
7D5.9%
1D
ポートフォリオ価値
表示

Canopy Growth Corporation

NasdaqGS:CGC 株式レポート

時価総額:US$402.5m

Canopy Growth(CGC)株式概要

キャノピー・グロース・コーポレーションはその子会社とともに、カナダ、ドイツ、オーストラリアで大麻、ヘンプ、大麻関連製品の生産、流通、販売に従事している。 詳細

CGC ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長0/6
過去の実績0/6
財務の健全性5/6
配当金0/6

CGC Community Fair Values

Create Narrative

See what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.

Canopy Growth Corporation 競合他社

価格と性能

株価の高値、安値、推移の概要Canopy Growth
過去の株価
現在の株価CA$1.04
52週高値CA$2.38
52週安値CA$0.84
ベータ2.39
1ヶ月の変化-12.24%
3ヶ月変化-11.11%
1年変化-43.17%
3年間の変化-88.15%
5年間の変化-99.60%
IPOからの変化-96.85%

最新ニュース

Seeking Alpha Apr 23

Canopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling

Summary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha Apr 23

Canopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling

Summary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha Apr 22

Canopy Growth: Zombie Financials As Delisting Threat Looms

Summary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alpha
Seeking Alpha Mar 30

Cannabis Investors Should Sell Canopy Growth

Summary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alpha
Seeking Alpha Feb 17

Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak

Summary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha Feb 06

Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results

Summary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha Jan 22

Crashing Canopy Growth Is Still Not A Buy

Summary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking Alpha
Seeking Alpha Jan 11

Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty

Summary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alpha
Seeking Alpha Nov 10

Avoid Canopy Growth

Summary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking Alpha
Seeking Alpha Oct 05

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Summary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking Alpha
Seeking Alpha Aug 27

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

Summary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alpha
Seeking Alpha Jun 17

Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)

Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alpha
Seeking Alpha Jun 03

Canopy Growth: Another Ugly Cannabis Report

Summary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alpha
Seeking Alpha Apr 26

Canopy Growth Set For U.S. Cannabis Markets

Summary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking Alpha
Seeking Alpha Mar 22

Canopy Growth Is Climbing, But It Won't Last

Summary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alpha
Seeking Alpha Feb 06

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Summary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking Alpha
Seeking Alpha Jan 29

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Summary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alpha
Seeking Alpha Jan 14

Avoid Canopy Growth After Failed Equity Sale

Summary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alpha

株主還元

CGCUS PharmaceuticalsUS 市場
7D5.9%5.4%1.2%
1Y-43.2%44.3%28.7%

業界別リターン: CGC過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を下回りました。

リターン対市場: CGCは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is CGC's price volatile compared to industry and market?
CGC volatility
CGC Average Weekly Movement10.4%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: CGC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: CGCの 週次ボラティリティ は、過去 1 年間で16%から10%に減少しました。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
n/a960Luc Mongeauwww.canopygrowth.com

キャノピー・グロース・コーポレーションは子会社とともに、カナダ、ドイツ、オーストラリアで大麻、ヘンプ、大麻関連製品の生産、流通、販売に従事している。4つのセグメントを通じて事業を展開している:カナダ・カンナビス(Canada Cannabis)、国際市場カンナビス(International Markets Cannabis)、シュトルツ&ビッケル(Storz & Bickel)、ディス・ワークス(This Works)。同社は、ドライフラワーやプレロールジョイント、ソフトジェルカプセルなどのエキスや濃縮物、グミなどの大麻エディブル、大麻ベイプ、オイル、飲料、濃縮物などを提供している。同社はTweed、7ACRES、Deep Space、HiWay、Maitri、Twd.、Spectrum Therapeutics、Canopy Medical、Storz & Bickel、Wana、Claybourneブランド、DOJA、LivRelief、Ace Valley、Vertブランドで製品を販売している。同社は以前Tweed Marijuana Inc.として知られていたが、2015年9月にキャノピー・グロース・コーポレーションに社名を変更した。キャノピー・グロース・コーポレーションはカナダのスミスフォールズに本社を置いている。

Canopy Growth Corporation 基礎のまとめ

Canopy Growth の収益と売上を時価総額と比較するとどうか。
CGC 基礎統計学
時価総額US$402.47m
収益(TTM)-US$236.92m
売上高(TTM)US$201.52m
2.0x
P/Sレシオ
-1.7x
PER(株価収益率

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
CGC 損益計算書(TTM)
収益CA$278.39m
売上原価CA$204.45m
売上総利益CA$73.94m
その他の費用CA$401.24m
収益-CA$327.29m

直近の収益報告

Dec 31, 2025

次回決算日

Jun 15, 2026

一株当たり利益(EPS)-0.86
グロス・マージン26.56%
純利益率-117.57%
有利子負債/自己資本比率29.7%

CGC の長期的なパフォーマンスは?

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/25 02:36
終値2026/05/22 00:00
収益2025/12/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Canopy Growth Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23

アナリスト機関
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)